An Ontario man battling Stage 4 melanoma is facing roadblocks in accessing public funding for crucial out-of-country drug treatments after a legal battle with the province. Alex Shved, a 37-year-old father fighting cancer that has spread to his lungs and bones, fought Ontario Health Insurance Plan rejections to seek urgent therapy in the United States to extend his time with his young daughters.
After a successful court challenge, Shved is now dismayed by the government’s move to restrict access for patients in similar situations. Despite the courts ruling the government’s actions as unlawful, changes in the law have made those actions permissible.
OHIP had denied Shved’s oncologist’s request for tumour-infiltrating lymphocyte therapy in Florida, citing the therapy’s consideration for public funding in Ontario. A recent Divisional Court decision found OHIP’s reasoning lacking and ordered a reconsideration.
However, following the ruling, OHIP rejected Shved’s request once more, and Health Minister Sylvia Jones announced regulatory amendments to only fund drugs abroad if they are already funded provincially but temporarily unavailable.
Shved, who has explored various treatments since his diagnosis in 2020, is particularly interested in TIL therapy, where immune cells are extracted, multiplied, and reinfused to combat cancer. While a version of this therapy is under review for possible funding, the lengthy process raises concerns for patients with urgent needs.
Critics like Adil Shamji, an Ontario Liberal health advocate, argue that the new regulations create a challenging situation for patients who cannot wait for years for drug approvals. They see the changes as a harsh commodification of people’s lives, limiting access to life-saving treatments.
Keyphrase: Ontario public funding restrictions
